Stoke Q3 net loss $38.3M ($0.65/sh); Phase 3 EMPEROR >20 randomized

Stoke Therapeutics, Inc.

2025-Q3 EPS reported $0.85 revenue$183,018,000

Net loss $38.3M ($0.65/sh) vs $26.4M ($0.47) in Q3 2024; revenue $10.6M vs $4.9M.
Cash $328.6M as of Sep 30; $48.7M from Oct share sales; funded to mid-2028.
Phase 3 EMPEROR: >20 patients randomized, ~35 in screening; enrollment on track for H2 2026.
FDA meeting planned before year-end to discuss expedited regulatory pathways for zorevunersen.
Ian F. Smith appointed permanent CEO (was interim); Arthur Tzianabos resumes Chairman role.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.